The University of North Carolina at Chapel Hill

Qualcomm Incorporated

Icahn School of Medicine at Mount Sinai

The Nielsen Comapny (US), LLC

Jing Liu

Xiaodong Wang

Stephen Frye

Dmitri Kireev

Weihe Zhang

Jian Jin

Michael R Sheppard

Edward Murphy

Kurt William Otte

Chao Yang

Jon James Anderson

Ludo Daemen

Matthias Brehler

Edmond Wong

Beate Sissenich

Xufen Yu

Jonathan Lee Sullivan

Brian Clarke Banister

Arthur James Neufeld

Dipti Umesh Shah

Andrew Louis McIver

Ramon Parsons

Kuang-Hsuan Tu

Xiaobao Yang

Poulikos Poulikakos

Bijan B Tuysserkani

Gang Wang

Tamer Ahmed

Dongxu Li

Md Kabir

Hyerin Yim

Jieli Wei

Olabode O Oyeneye

Matthew Zipoy

Jianping Hu

Jia Xu

John Charles May

Yan Xiong

Weihe Zhaug

Zoi Karoulia

Xuewei Wu

Kurt W Otte

A disclosed example includes determining a plurality of cross-demographic total census parameter values based on ratios of third-party impression counts and third-party audience sizes, selecting a first cross-demographic total census parameter value as an upper bound constraint from the plurality of cross-demographic total census parameter values based on comparisons between ones of the plurality of cross-demographic total census parameter values, selecting a second cross-demographic total census parameter value from the plurality of cross-demographic total census parameter values based on the second cross-demographic total census parameter value being less than the upper bound constraint, determining a first census-level audience size based on the second cross-demographic total census parameter value, and determining a first census-level impression count based on the second cross-demographic total census parameter value.

Methods and apparatus to estimate census level impressions and unique audience sizes across demographics

Methods, apparatus, systems, and articles of manufacture are disclosed to determine unique audience size via clustered data. An example apparatus includes memory, machine readable instructions, and processor circuitry to at least one of execute or instantiate the machine readable instructions. The example processor circuitry is to form a first matrix identifying matching and non-matching instances of first values of respective demographics of an audience of media and second values of the respective demographics. Also, the processor circuitry is to normalize the first matrix to generate an account sharing adjustment matrix. Additionally, the processor circuitry is to apply the account sharing adjustment matrix to a vector of one or more counts of impressions of the media to correct for one or more members of the audience that share a user account registered with a database proprietor, the one or more counts of the impressions corresponding to the respective demographics.

Methods, apparatus, and articles of manufacture to determine unique audience size via clustered data

Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.

WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use

This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use

Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.

Compositions and methods for treating CDK4/6-mediated cancer

Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.

Serine threonine kinase (AKT) degradation / disruption compounds and methods of use

An example apparatus to determine census-based audience metrics of media across multiple demographics includes an audience size determiner to determine a first census-level audience size based on a third-party audience size, a third-party impression count, and a first cross-demographic total census parameter value; an impression counts determiner to determine a first census-level impression count based on the third-party audience size, the third-party impression count, and the first cross demographic total census parameter value; and a verifier to determine whether the first cross-demographic total census parameter value satisfies a constraint based on the first census-level impression count; and when the constraint is not satisfied the verifier to: (a) discard the first cross-demographic total census parameter value, and (b) select a second cross-demographic total census parameter value, the second cross-demographic total census parameter value to determine a second census-level audience size and a second census-level impression count to satisfy the constraint.

Compounds of Formula I: wherein: one of X and X' is N and the other of X and X&#x2032; is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Pyrrolopyrimidine compounds for the treatment of cancer

Compounds of Formula I or II: are described, along with pharmaceutical compositions containing the same and methods of using such compounds for the treatment of cancer.

Pyrimidine compounds for the treatment of cancer

Compound of Formula I: are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.

Pyrazolopyrimidine compounds for the treatment of cancer

Compounds of Formula I are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof.

Compound of Formula (I): are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer. 

The ectopic expression of Mer receptor tyrosine kinase (Mer) has been identified as a tumor cell survival gene product in Acute Lymphoblastic Leukemia (ALL) cells and a potential cause of ALL chemoresistance. Hence, we investigated whether the development of small molecule Mer inhibitors was possible. A first aspect of the present invention is a compound (sometimes referred to as an 'active compound' herein) of Formula I, IA, or IB. 

Embodiments include a method of signal processing in which each of a set of individual estimates of a transmitted symbol is added to a combined symbol estimate based on a relation between a signal quality value corresponding to the individual estimate and a threshold value, where the threshold value is based on a maximum among the signal quality values.

Systems, methods, and apparatus for establishing finger lock state

Growing community of inventors

Jersey City, NJ, United States of America

Jing Liu